AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17413092
Drug: High physical
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High physical activity (HPA) treatment with a goal of 2500 kcal/wk
Trial: 17413092
Drug: Standard behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavioral treatment (SBT) with an exercise goal of 1000 kcal/wk
Trial: 1538178
Drug: Iontophoresed morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoresed morphine HCl
Trial: 1538178
Drug: Iontophoresed lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoresed lactated ringers solution
Trial: 6434024
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral plus nasal beclomethasone diproprionate
Trial: 29752853
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 mcg kg‐1
Trial: 26350351
Drug: Goserelin 10.8
RxNorm normalized name: goserelin 10.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin 10.8 mg (3-monthly)
Trial: 26350351
Drug: Goserelin 3.6
RxNorm normalized name: goserelin 3.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin 3.6 mg (monthly)
Trial: 24660763
Drug: Carbonyl iron
RxNorm normalized name: Carbonyl Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbonyl iron (45 mg daily)
Trial: 19884264
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg daily for 12 months
Trial: 18020541
Drug: Transdermal drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal drug delivery system (TDDS) of metoprolol tartrate applied for 48 hours
Trial: 18020541
Drug: Conventional marketed
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional marketed tablet of metoprolol tartrate (100 mg)
Trial: 18020541
Drug: Transdermal drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal drug delivery system (TDDS) of metoprolol tartrate
Trial: 12474653
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO4) used as an adjuvant to anesthetics; shock-dose injection of 30-50 mg/kg and continual infusion at 500 mg/h for 20 hours.
Trial: 7722125
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion alone
Trial: 28508455
Drug: Alpha-blocker only
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-blocker only (n=111)
Trial: 28508455
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (alpha-blocker + anticholinergic, n=110)
Trial: 18392221
Drug: Radioimmunoscintigraphy (RIS)
RxNorm normalized name: Ri-Mag Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioimmunoscintigraphy (RIS) using monoclonal antibody against human milk fat globule labeled with technetium-99m (99m)Tc
Trial: 14534715
Drug: beta-carotene (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-carotene (75 mg/day for 3-month cycles with one month intercycle intervals for 3 years)
Trial: 2059815
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg tamoxifen daily and optimal surgery
Trial: 6735044
Drug: Gelox (shielding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelox (shielding antacid) after 500 mg of AAS
Trial: 30696977
Drug: Cholecalciferol (vitamin
RxNorm normalized name: cholecalciferol (vitamin D3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (vitamin D) 50,000 IU weekly for 3 months
Trial: 25205201
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg twice daily plus amoxicillin 1 g thrice daily for 14 days
Trial: 25205201
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg twice daily plus amoxicillin 1 g thrice daily for 14 days
Trial: 10515673
Drug: HRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT with progestin for 10 days during 12 week cycles of estrogen (17beta‐estradiol 2 mg per day, reduced to 1 mg during last 6 days)
Trial: 10515673
Drug: HRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT with progestin for 10 days during monthly cycles of estrogen (17beta‐estradiol 2 mg per day, reduced to 1 mg during last 6 days)
Trial: 7640054
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of ifosfamide (9 g/m2 over 72 h)
Trial: 7640054
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of ifosfamide (3 g/m2 every 24 h for 3 days)
Trial: 1904568
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg transdermal E2 patches for 2 weeks, followed by 0.1 mg patches for 4 weeks (immediate ERT)
Trial: 1904568
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg transdermal E2 patches for 2 weeks, followed by 0.1 mg patches for 4 weeks (delayed ERT)
Trial: 1904568
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg transdermal E2 patches
Trial: 26695758
Drug: Natesto™ Testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natesto™ Testosterone Nasal Gel (11 mg b.i.d. or 11 mg t.i.d.)
Trial: 26695758
Drug: Natesto™ Testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natesto™ Testosterone Nasal Gel (titration arm)
Trial: 26695758
Drug: Natesto™ Testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natesto™ Testosterone Nasal Gel (fixed-dose arm)
Trial: 26695758
Drug: Natesto™ Testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natesto™ Testosterone Nasal Gel
Trial: 23474648
Drug: High-protein/calorie parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein/calorie parenteral nutrition (HPC-PN)
Trial: 23474648
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard parenteral nutrition)
Trial: 23168752
Drug: Long-acting reversible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting reversible contraceptive (LARC) methods (IUDs and implants) provided at no cost
Trial: 28805670
Drug: Salacia Chinensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salacia Chinensis (300 mg)
Trial: 28805670
Drug: Salacia Chinensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salacia Chinensis (500 mg)
Trial: 28805670
Drug: Salacia Chinensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salacia Chinensis (300 mg) or (500 mg)
Trial: 25623753
Drug: Subcutaneous delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous delivery of trastuzumab via Single Injectable Device (SID)
Trial: 25623753
Drug: Subcutaneous delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous delivery of trastuzumab via hand-held syringe (HHS)
Trial: 25623753
Drug: Intravenous delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous delivery of trastuzumab
Trial: 21406054
Drug: Various antiretroviral
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various antiretroviral drugs
Trial: 21406054
Drug: Older and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older and lesser used drugs
Trial: 21406054
Drug: Recently approved
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recently approved drugs
Trial: 21406054
Drug: Compounds under
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compounds under investigation
Trial: 25891543
Drug: Caffeine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (150 mg daily at 10 a.m.)
Trial: 25891543
Drug: Placebo (n=2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (n=2) or no treatment (n=1)
Trial: 15868252
Drug: Topical GTN
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical GTN (5 ml, 1 mg/ml)
Trial: 7726425
Drug: Lidocaine 45
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 45 mg and epinephrine 15 micrograms (Group 5)
Trial: 7726425
Drug: Lidocaine 45
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 45 mg (Group 2)
Trial: 7726425
Drug: Lidocaine 45
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 45 mg and epinephrine 5 micrograms (Group 3)
Trial: 7726425
Drug: Lidocaine 45
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 45 mg and epinephrine 10 micrograms (Group 4)
Trial: 2029201
Drug: Long-term administration
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term administration group (L) receiving Cyclophosphamide (CPA) at a total dose of 25 g/m2 over 18 months
Trial: 2029201
Drug: Short-term administration
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term administration group (S) receiving Cyclophosphamide (CPA) at a total dose of 6 g/m2 over 6 months
Trial: 2029201
Drug: Long-term administration
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term administration group (L)
Trial: 117442
Drug: Pre-operative parenteral
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative parenteral nutrition over a 7-10 day period
Trial: 29420227
Drug: Azithromycin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 7.5 mg/kg, 5 days/week for 4 weeks and 3 days/week for another 4 weeks with metronidazole 20 mg/kg/day for 8 weeks (group 1)
Trial: 28194668
Drug: Raw rhubarb
RxNorm normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raw rhubarb solution (250 cases drank a raw rhubarb soak solution per 3 hours until defecation after ERCP)
Trial: 28194668
Drug: Raw rhubarb
RxNorm normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raw rhubarb solution
Trial: 14764781
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone application (Virormone, 5 mg) for 8 or 12 hours
Trial: 10833890
Drug: Moxonidine 40
RxNorm normalized name: moxonidine 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 40 mg alone in the morning
Trial: 10833890
Drug: Moxonidine 40
RxNorm normalized name: moxonidine 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 40 mg in combination with melatonin 3 mg overnight
Trial: 9752921
Drug: Aspiration and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspiration and injection of steroid
Trial: 8411611
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg in the morning
Trial: 3085212
Drug: Phenoxymethylpenicillin, 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenoxymethylpenicillin, 12.5 mg/kg body weight, administered orally 30-240 min before surgery
Trial: 28651550
Drug: C3 (2
RxNorm normalized name: Codeine.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C3 (2 mg/mL) applied four times daily for 2 weeks
Trial: 17259696
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 600 mg/day for 12 weeks
Trial: 11756055
Drug: Low-fat, complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, complex carbohydrate diet (LF-CC)
Trial: 9803986
Drug: Methotrexate (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (oral or intramuscular doses weekly)
Trial: 7659386
Drug: Jet nebulizer
RxNorm normalized name: Pari LC Jet Nebulizer Plus RE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet nebulizer (Respirgard II) with 2 ml volume fill (R2)
Trial: 7659386
Drug: Ultrasonic nebulizer
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic nebulizer (Ultraneb 99) with 4 ml volume fill (U4)
Trial: 26037798
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and gemcitabine (CisGem) chemotherapy
Trial: 23569146
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) for 12 weeks
Trial: 23569146
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy alone (non‐CRT group)
Trial: 17093157
Drug: Two tests
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tests of glucose solution as the reference
Trial: 15286687
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) and Cyclosporin A (CsA) combination
Trial: 9394582
Drug: Aspirin discontinued
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin discontinued two days before operation (Group I)
Trial: 9394582
Drug: Aspirin continued
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin continued up to operation (Group II)
Trial: 9394582
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no aspirin for at least seven days before operation)
Trial: 3678266
Drug: Propafenone (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (450 mg to 900 mg per day)
Trial: 29082595
Drug: Nitrate supplementation
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate supplementation (25 ml beetroot juice, one shot per day for 3 days)
Trial: 19947907
Drug: SC ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC ceftriaxone with rHuPH20 (350 mg/mL)
Trial: 15655130
Drug: Lipoic acid
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoic acid 300 mg/d
Trial: 15655130
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg/d and Lipoic acid 300 mg/d
Trial: 12805489
Drug: UK‐279,276 (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK‐279,276 (1.0 mg/kg)
Trial: 12805489
Drug: UK‐279,276 (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK‐279,276 (1.5 mg/kg)
Trial: 12805489
Drug: UK‐279,276 (0.06,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK‐279,276 (0.06, 0.1, 0.2, 0.5, 1.0, 1.5 mg/kg)
Trial: 12805489
Drug: UK‐279,276 (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK‐279,276 (1.0 and 1.5 mg/kg)
Trial: 6208468
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with cyclophosphamide combined with Ara‐C
Trial: 6208468
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with Cyclo‐C
Trial: 6208468
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of VP‐16 and CCNU to maintenance therapy
Trial: 28145073
Drug: Dermalax implant
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermalax implant plus™
Trial: 19705681
Drug: Integrated ICPS
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated ICPS drug and employment counseling (n = 12)
Trial: 19705681
Drug: ICPS drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICPS drug counseling control condition (n = 11)
Trial: 17012300
Drug: Tigecycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline (100 mg intravenous infusion over 30 min)
Trial: 12431972
Drug: Study agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study agent (cytostatic agent)
Trial: 9927265
Drug: Low-dose vancomycin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vancomycin (500 mg/d)
Trial: 9927265
Drug: High-dose vancomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vancomycin (2 g/d)
Trial: 9927265
Drug: Metronidazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (1 g/d)
Trial: 8745203
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and sulfonylurea
Trial: 7004720
Drug: Bendrofluazide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide (10 mg daily) for 3 days
Trial: 7004720
Drug: Bendrofluazide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide (10 mg daily) for 10 weeks
Trial: 6882732
Drug: Malted cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malted cocoa drink fortified with FePO4 and ascorbic acid (1 mg/g powder)
Trial: 26758281
Drug: Ebselen (3600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebselen (3600 mg over 24 h)
Trial: 22009510
Drug: 550 mg
RxNorm normalized name: xylitol 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 550 mg oral naproxen sodium plus active TENS
Trial: 22009510
Drug: 550 mg
RxNorm normalized name: xylitol 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 550 mg oral naproxen sodium plus placebo TENS
Trial: 18581586
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of parecoxib
Trial: 18581586
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of proparacetamol
Trial: 20179234
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant endocrine treatment
Trial: 12172717
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tenoxicam in 25 ml normal saline
Trial: 12172717
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg morphine in 25 ml normal saline
Trial: 12172717
Drug: 25 ml
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml normal saline (control)
Trial: 10199760
Drug: Lipid infusion
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid infusion (10% at 150 mL/h)
Trial: 7493372
Drug: IFN-alpha (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha (3 million units daily for 14 days)
Trial: 7493372
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no IFN-alpha treatment)
Trial: 2097909
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine 5%
Trial: 2097909
Drug: Topical benzocaine
RxNorm normalized name: benzocaine Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzocaine 20% vs Topical lidocaine 5%
Trial: 2097909
Drug: Topical anesthetics
RxNorm normalized name: topical anesthetics (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthetics (benzocaine 20% and lidocaine 5%)
Trial: 18799080
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) treatment
Trial: 30807516
Drug: Intravitreal 0.5‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal 0.5‐mg ranibizumab
Trial: 28800951
Drug: High-concentration contrast
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration contrast media (HCCM) injection protocol with low tube current (effective mAs reduced by a factor of 0.6, HCCM 400 mgI/mL)
Trial: 28800951
Drug: Low concentration
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low concentration contrast medium (300 mgI/mL) with automatic mAs
Trial: 23787155
Drug: High Hb
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Hb group (target Hb 11.0 ≤ target Hb ≤ 13.0 g/dL with darbepoetin alfa)